A Proven Material

Since the development of Biodesign, this new category of tissue repair has been studied and written about extensively in medical journals. To date, more than 700 articles have been published about the material from which Biodesign is created (originally called Surgisis or SIS), more than any other biologic graft. Plus, more than 190 of these articles discuss studies using this technology in humans.

In fact, Biodesign is supported by Level 1 clinical evidence through randomized controlled trials in multiple applications. Recent 5 year data has further supported evidence of Biodesign’s 4 key benefits: signals the body, resistant to infection, complete remodeling and long-term strength. Biodesign is the only biologic graft to have such long-term data supporting its use.

This revolutionary technology is available for use in nine procedural areas, has been distributed to 86 countries and used in more than one million procedures.

Search the Resource Library for more Biodesign information including journal articles, videos, animations and other educational materials.

Cook Biotech Incorporated (CBI) was founded in 1995 to research, develop and manufacture commercial medical products from bioscaffolds, including Biodesign. Learn more about Cook Biotech.